<DOC>
	<DOCNO>NCT00841880</DOCNO>
	<brief_summary>The objective study compare reduction office seat systolic blood pressure ( BP ) follow 8 week regimen ramipril 5mg plus felodipine 5mg versus ramipril 10mg . To compare response rate ( define office systolic blood pressure ( SBP ) / Diastolic blood pressure ( DBP ) reduce 10mmHg baseline ) , BP control rate ( define SBP &lt; 140mmHg and/or DBP &lt; 90mmHg ) SBP &lt; 130 mmHg /or DBP &lt; 80 mmHg diabetes , chronic kidney disease , know Coronary Arterial Disease ( CAD ) CAD equivalent , 10-year Framingham risk score &gt; 10 % . To ascertain safety tolerability ramipril/felodipine versus ramipril Taiwanese population . To compare compliance fix dose combination ramipril/felodipine versus ramipril treatment .</brief_summary>
	<brief_title>China Medical University Hospital ( CMUH ) Triapin Listing</brief_title>
	<detailed_description />
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Felodipine</mesh_term>
	<criteria>Inclusion criterion : Uncontrolled essential hypertension define office SBP/DBP &gt; 140/90 &gt; 130/80 mmHg compelling indication ( diabetes mellitus , chronic kidney disease , know CAD CAD equivalent 10year Framingham risk score &gt; 10 % ) Previously untreated , previously treat single antihypertensive therapy usual dose last 4 week Exclusion criterion : Female pregnant breast feeding Office DBP &gt; 110mmHg office SBP &gt; 180mmHg Hypersensitivity ramipril , felodipine excipients Bilateral stenosis renal artery , unilateral stenosis single kidney History intolerance ACE inhibitor History significant renal disease include : serum creatinine &gt; 3.0 mg/dl , creatinine clearance &lt; 30 ml/min History hereditary and/or idiopathic angioedema ; angioedema associate previous ACEI Significant cardiovascular disease , multiple drug allergy , bronchospastic disease malignancy require current medication Hepatic disease indicate follow : Serum Glutamooxaloacetate Transferase ( SGOT ) Serum Glutamopyruvate Transferase ( SGPT ) &gt; 3 x upper limit normal , serum bilirubin &gt; 2 x upper limit normal Any condition therapy , investigator 's opinion , indicated product ( ) label may pose risk patient interfere study objective . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>